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he Search for
yocardial Protection
s There Still Hope?*
hristopher B. Granger, MD, FACC,
anesh R. Patel, MD
urham, North Carolina
here are few pursuits in medicine that have yielded so little
rom so much effort as the search for myocardial protection
herapies, which began in earnest over 30 years ago (1). The
earch has been warranted because ischemic heart disease is
rowing as the world’s leading cause of death and disability.
ew therapy for the acute manifestation of myocardial
nfarction aimed at reducing myocardial damage and im-
roving clinical outcomes is a high priority.
See page 397
What is known about myocardial protection? Ischemic
reconditioning is an important physiological mechanism, is
ediated in part through adenosine and protein kinase C
ctivation (2), and likely explains some of the heterogeneity
n patient outcomes with acute myocardial infarction. Doz-
ns of treatments reduce infarct size in animal models of
schemia-reperfusion. However, the relevance of most of
hese animal models to human acute myocardial infarction
s questionable (3). Generally, when tested in humans,
reatments effective in experimental models have not been
hown to reduce infarct size. The concept of providing
omplementary clinical benefit to reperfusion therapy, how-
ver, is well founded. Angiotensin-converting enzyme in-
ibitors provide an example of a therapy that improves
utcome in the early hours and days after acute myocardial
nfarction (MI), 40% of the early survival benefit occurring
n the first day of treatment (4), in part through modifying
entricular remodeling.
Is there any hope for myocardial protection based on
linical trial results? In humans, some therapies do seem to
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nd the Medicines Company.educe myocardial damage in the ischemia-reperfusion set-
ing, including adenosine in acute myocardial infarction
5,6) and cariporide in coronary artery bypass surgery (7).
his is important because it provides support to the concept
hat myocardial protection can be accomplished in the
linical setting. However, the benefits so far have either not
een large enough to warrant further clinical development
r have been counterbalanced by adverse effects (7).
The care of acute myocardial infarction was transformed
y reperfusion therapy, which established the relationship
etween faster, more complete myocardial perfusion and
mproved survival. But reperfusion therapy, both in animal
odels and in clinical trials, comes at a cost, with an early
azard that is not completely explained by bleeding com-
lications (8). A variety of approaches have been tried to
vercome “reperfusion injury” and protect the myocardium,
ncluding inhibiting the inflammatory response, modifying
armful intracellular calcium influx, stabilizing membranes,
educing apoptosis, enhancing metabolic pathways to pro-
ide resistance to ischemic damage, improving energy me-
abolism, inducing therapeutic hypothermia, and improving
xygen delivery. Several of these approaches have been
imed at improving microvascular function, which may be
specially important with primary percutaneous coronary
ntervention (PCI) where the epicardial artery is effectively
pened in the vast majority of cases, but tissue-level perfu-
ion may be incomplete.
Aqueous oxygen is intended to improve myocardial oxy-
en delivery and microvascular function. Initial experiments
n animal models of reperfusion of myocardial infarction
howed that aqueous oxygen had beneficial effects on both
entricular function and microvascular blood flow as mea-
ured by radiolabeled microspheres (9). Additionally, small
linical pilot studies suggested that aqueous oxygen may
revent adverse remodeling and improve ventricular func-
ion (10,11).
In this issue of the Journal, O’Neill et al. (12) report a
ulticenter randomized trial of 269 patients undergoing
rimary or rescue PCI within 24 h of symptom onset
valuating hyperoxemic reperfusion with aqueous oxygen.
mportantly, patients with normal epicardial flow at the
ime of initial infarct angiography (Thrombolysis In Myo-
ardial Infarction flow grade 3 before intervention) were
xcluded. Patients were randomized after successful PCI to
eceive aqueous oxygen (TherOx Inc., Irvine, California)
elivered through a novel system that mixes oxygen with
lood, achieving a pO2 of 760 to 1,000 mm Hg, or
ormoxemic blood autoreperfusion, delivered into the prox-
mal portion of the infarct-related artery. Each patient had
comprehensive and complementary array of evaluations,
ncluding continuous ST-segment monitoring; serial con-
rast echocardiography at 24 h, 1 month, and 3 months; and
nfarct size as measured by 99mTc-sestamibi single-photon
mission computed tomography imaging at 14 to 21 days.
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July 31, 2007:406–8 Editorial Commentegional wall motion, ST-segment resolution, or final in-
arct size. In a post-hoc analysis, there was improved
egional function in patients with anterior MIs treated
ithin 6 h of symptom onset.
The trial team successfully completed a rigorous and
hallenging clinical trial. The trial did not show a benefit of
yperoxemic reperfusion in acute MI. When such a trial
hows no benefit in the overall population, subgroup find-
ngs are hypothesis-generating only. Whether aqueous ox-
gen treatment is ineffective or whether there was some
enefit that was either not detected or was present in certain
ubpopulations is not known. What lessons can be learned
or future research?
The negative findings are not surprising, and this study
einforces the pattern of negative clinical studies of myocar-
ial protection. It is likely that failure to replicate experi-
ental data in clinical trials relates, at least in part, to the
ack of relevance of the highly controlled ischemia and
eperfusion in animal models compared with the more
omplex reperfusion that occurs in patients. The choice of
atient population may be crucial in evaluation of myocar-
ial protection. Agents directed toward improving the
yocardial reperfusion itself are time-limited to the period
nown to define when myocardial salvage occurs (i.e., the
rst 3 to 6 h). Thus, limiting acute inflammatory damage to
mprove microvascular function might be most effective in
atients presenting relatively early after symptom onset and
ith large (anterior) myocardial infarctions. Several clinical
rials have suggested more benefit in anterior than inferior
I location (6,12,13) and in earlier-presenting patients
12,14). Studying patients with large infarctions, and per-
aps anterior MI in particular, makes sense because these
re higher-risk patients in most need of better therapy.
ocusing on the very early presenters creates a paradox,
owever—the earliest-presenting patients have such good
utcomes that it will be difficult to show incremental value.
n contrast to what was accomplished in this study, initiat-
ng the therapy as early as possible (and before reperfusion)
ay be important, although complex delivery needs may
imit the practical application of therapies such as aqueous
xygen. As the investigators acknowledge, in this study the
nclusion of patients with symptoms up to 24 h may have
imited the ability to show a treatment difference. It is
lausible, and a reasonable hypothesis for further study, that
he subset of patients with anterior MI of 6 h is the
opulation most likely to benefit.
On the other hand, treatment intended to prevent apo-
tosis, to modify remodeling, and to enhance regeneration
ight provide benefits to patients with longer delays to
eperfusion. A complicating factor is that the exact mech-
nism of benefit, if present, is not known for many potential
yocardial protection therapies.
Another possibility is that the methods for detecting
elevant reductions in infarct size in phase II trials of
yocardial protection have simply been too insensitive. Thexploratory multimarker analysis used in the present studyas been the best approach to guide whether there is
ufficient probability of success to proceed to clinical out-
omes trials. Another tool, delayed enhancement imaging
ith cardiac magnetic resonance (CMR), seems to be ready
or use in multicenter trials. Studies comparing delayed-
nhancement CMR with single-photon emission computed
omography have shown higher resolution for smaller (often
ubendocardial) infarctions (15). The resolution of CMR
lso allows evaluation of the transmural extent of infarction
nd that relates to subsequent improvement in myocardial
unction (16). Finally, CMR allows visualization of areas
f microvascular obstruction in necrotic and perinecrotic
egions (17,18). Cardiac magnetic resonance has been
erformed in both animal models and in multicenter
linical trials (19) evaluating myocardial protection. In a
ulticenter study of cell therapy (20), CMR was able to
etect small improvements in global and regional left
entricular function.
Is the continued search for myocardial protection a
tubborn exercise in futility, or an elusive opportunity to
ventually improve patient care? Although any individual
herapy has a high risk for failure, the likelihood is that with
mproved understanding and refined clinical development
rograms, selected approaches to myocardial protection will
ventually succeed.
eprint requests and correspondence: Dr. Christopher B.
ranger, Duke Clinical Research Institute, Duke University Medical
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